Bexxar tositumomab regulatory update

The FDA informed CLTR and partner SmithKline Beecham (Philadelphia, Penn.) that their BLA for Bexxar to treat relapsed or refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma w...